| Autor: |
Alejandro Olivares-Hernández, Edel del Barco Morillo, José Pablo Miramontes-González, Luis Figuero-Pérez, Luis Pérez-Belmonte, Javier Martín-Vallejo, Teresa Martín-Gómez, Roberto Escala-Cornejo, Rosario Vidal-Tocino, Lorena Bellido Hernández, Rogelio González Sarmiento, María Dolores Ludeña de la Cruz, Juan Jesús Cruz-Hernández, Carmen Parra Pérez |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Frontiers in Bioscience-Landmark, Vol 27, Iss 3, p 088 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2768-6701 |
| DOI: |
10.31083/j.fbl2703088 |
| Popis: |
Background: Determining predictive biomarkers for immune checkpoint inhibitors (ICIs) is a current challenge in oncology. Previous studies on non-small cell lung cancer (NSCLC) have shown how TP53 gene mutations are correlated with different responses to ICIs. Strong and diffuse immuno-expression of p53 by immunohistochemistry (IHC) is interpreted as a likely indicator of a TP53 gene mutation. We aimed to assess the p53 protein expression via IHC in NSCLC as a predictive biomarker of the response to ICIs. Methods: This was a retrospective hospital-based study of patients with NSCLC treated with Nivolumab in the University Hospital of Salamanca. All diagnostic biopsies were studied via IHC (measuring p53 protein expression, peroxidase anti-peroxidase immunohistochemistry technique using Leica BOND Polymer development kits). Survival analysis was performed by subgroups of expression of p53 and other factors using the Kaplan-Meier estimator and Cox proportional-hazards model. Results: Seventy-three patients were included (59 men and 14 women). The median age was 68 (44–84) years. Thirty-six biopsies were adenocarcinoma, 34 were squamous, and three were undifferentiated. In 41 biopsies (56.2%), the cellular expression of p53 was |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
